| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
CASH FLOWS FROM OPERATING ACTIVITIES | |||||||||
Net loss | |||||||||
-45,362 | -27,471 | - | - | - | - | - | - | - | - |
Net loss | |||||||||
- | - | -10,770 | -9,453 | -7,206 | -26,202 | -5,738 | -14,545 | -4,558 | -8,101 |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||
Depreciation and amortization for property and equipment | |||||||||
603 | 366 | - | - | - | - | - | - | - | - |
Depreciation and amortization for property and equipment | |||||||||
- | - | 117 | 66 | 68 | 48 | 17 | 20 | 38 | 70 |
Net loss on disposal of property and equipment | |||||||||
-2 | -5 | 0 | 12 | 0 | - | - | - | 8 | 2 |
Amortization of intangible assets | |||||||||
1,550 | 1,305 | 0 | - | - | - | - | - | - | - |
Write down of obsolete inventories | |||||||||
152 | 0 | - | - | - | - | - | - | - | - |
Loss on disposal of intangible assets | |||||||||
408 | 0 | - | - | - | - | - | - | - | - |
Impairment of equipment | |||||||||
386 | 0 | - | - | - | - | - | - | - | - |
Investment impairment loss | |||||||||
- | - | - | - | - | - | - | - | - | 28 |
Stock-based compensation expense | |||||||||
7,310 | 6,119 | 650 | 2,995 | 1,541 | 2,189 | 2,044 | 978 | 609 | 271 |
Acquired in-process research and development | |||||||||
6,967 | 553 | 0 | - | - | - | - | - | - | - |
Change in fair value of investment in equity securities | |||||||||
288 | 320 | 0 | - | - | - | - | - | - | - |
Acquired in-process research and development | |||||||||
- | - | - | - | - | 19,681 | 0 | - | - | 3,000 |
Realized gain on sale of short-term investment | |||||||||
- | - | - | - | - | - | - | - | 0 | - |
Non-cash interest | |||||||||
1 | 1 | 7 | 26 | 74 | 25 | 0 | 10,041 | 0 | 48 |
Change in fair value of contingent rights | |||||||||
- | - | 19 | 6 | -27 | -11 | 0 | - | - | - |
Changes in operating assets and liabilities: | |||||||||
Accounts receivable | |||||||||
1,293 | 0 | - | - | -23 | 23 | -669 | -1,263 | -817 | -536 |
Inventories | |||||||||
4,411 | 283 | - | - | - | - | - | - | - | - |
Prepaid expenses and other assets | |||||||||
-5,751 | 6,944 | 0 | -86 | 122 | 56 | 90 | 9 | -72 | 44 |
Right of use assets | |||||||||
-424 | 0 | - | - | - | - | - | - | - | - |
Accounts payable | |||||||||
4,001 | -1,097 | - | - | - | - | - | - | - | - |
Accounts payable | |||||||||
- | - | 849 | 180 | 129 | 352 | -102 | 51 | -897 | -617 |
Payable to related party | |||||||||
153 | -2,228 | 2,228 | 0 | - | - | -86 | 86 | 0 | - |
Accrued liabilities and other liabilities | |||||||||
-173 | 770 | 495 | 81 | 5 | 1 | 11 | -99 | -344 | -149 |
Net cash used in operating activities | |||||||||
-23,243 | -28,584 | -6,402 | -6,023 | - | - | - | - | -4,272 | -4,959 |
CASH FLOWS FROM INVESTING ACTIVITIES | |||||||||
Net cash used in operating activities | |||||||||
- | - | - | - | -5,513 | -3,995 | -3,275 | -2,212 | - | - |
Proceeds from disposal of property and equipment | |||||||||
0 | 1 | 0 | 158 | 0 | - | - | - | - | - |
Proceeds from sale of short-term investment | |||||||||
- | - | - | - | - | - | - | - | 26 | - |
Proceeds from sale of assets | |||||||||
- | - | - | - | - | - | - | - | 56 | 2 |
Purchases of property and equipment | |||||||||
427 | 1,131 | 934 | 223 | 25 | 231 | 42 | 48 | 6 | 3 |
Purchase of land use rights | |||||||||
6,626 | 0 | - | - | - | - | - | - | - | - |
Cash paid to acquired in-process research and development | |||||||||
6,967 | 0 | - | - | - | 234 | 0 | - | - | - |
Cash paid to acquire equity securities in Black Belt Tx Limited | |||||||||
2,250 | 0 | - | - | - | - | - | - | - | - |
Cash paid to acquire equity securities in Juventas Cell Therapy Ltd | |||||||||
11,788 | 0 | - | - | - | - | - | - | - | - |
Acquisition of Abbreviated New Drug Applications and related items | |||||||||
0 | 20,643 | 0 | - | - | - | - | - | - | - |
Net cash (used in) provided by investing activities | |||||||||
- | - | - | - | -25 | -466 | -42 | -48 | - | - |
Net cash provided by (used in) investing activities | |||||||||
-28,058 | -21,773 | -934 | -64 | - | - | - | - | 77 | -1 |
CASH FLOWS FROM FINANCING ACTIVITIES | |||||||||
Repayment of notes payable | |||||||||
1,500 | 0 | - | - | - | - | - | - | - | - |
Proceeds from issuance of convertible notes and warrants | |||||||||
- | - | - | - | - | - | - | 10,000 | 0 | - |
Debt issuance costs | |||||||||
- | - | - | - | - | - | - | 683 | 0 | - |
Proceeds from sale of common stock and warrants | |||||||||
- | - | - | - | - | - | 10,789 | 0 | 1,312 | 13,094 |
Repayment of loan | |||||||||
- | - | - | - | - | - | - | - | 757 | 8,553 |
Stock issuance costs | |||||||||
190 | 822 | 462 | 96 | 0 | - | 448 | 88 | 164 | 1,005 |
Proceeds from sale of common stock | |||||||||
182 | 87,990 | 23,870 | 28,146 | - | - | - | - | - | - |
Cash contribution from redeemable noncontrolling interest | |||||||||
20,000 | 0 | - | - | - | - | - | - | - | - |
Proceeds from sale of common stock | |||||||||
- | - | - | - | 0 | - | - | - | - | - |
Proceeds from exercise of stock options | |||||||||
854 | 258 | 325 | 0 | - | - | - | - | - | - |
Repurchase of stock options to satisfy tax withholding obligations | |||||||||
367 | 117 | 0 | - | - | - | - | - | - | - |
Proceeds from exercise of warrants | |||||||||
3,275 | 4,961 | 0 | - | - | - | - | - | - | - |
Payment of deferred offfering costs | |||||||||
209 | 0 | - | - | - | - | - | - | - | - |
Proceeds from exercise of options and warrants | |||||||||
- | - | - | - | - | - | 59 | 1 | - | - |
Net cash provided by financing activities | |||||||||
- | - | - | - | 0 | - | 10,401 | 9,229 | - | - |
Net cash provided by financing activities | |||||||||
22,045 | 92,270 | 23,733 | 28,049 | - | - | - | - | 389 | 3,535 |
Effect of exchange rate change on cash and cash equivalents | |||||||||
-1,328 | -1,198 | 0 | - | - | - | - | - | - | - |
Net increase (decrease) in cash and cash equivalents | |||||||||
-30,584 | 40,715 | - | - | - | - | - | - | - | - |
Net increase in cash and cash equivalents | |||||||||
- | - | 16,397 | 21,961 | -5,538 | -4,461 | 7,082 | 6,968 | -3,805 | -1,426 |
Supplemental disclosure of cash flow information: | |||||||||
Interest paid | |||||||||
30 | 0 | - | - | - | - | - | - | - | - |
Interest paid | |||||||||
- | - | 0 | - | 7 | 0 | - | - | 7 | 573 |
Income taxes paid | |||||||||
0 | 0 | 0 | - | - | - | - | - | - | - |
Non-cash financing activity: | |||||||||
Common stock issued in connection with conversion of convertible notes and accrued interest | |||||||||
- | - | - | - | - | - | - | 10,144 | 0 | - |
Common stock issued in connection with conversion of preferred stock | |||||||||
- | - | - | - | - | - | - | 3,500 | 0 | - |
Warrant issued to placement agent | |||||||||
- | - | 28 | 0 | - | - | 115 | 0 | - | - |
Partial settlement of contingent rights derivative | |||||||||
- | - | 4,142 | 5,279 | 0 | - | - | - | - | - |
Disposal of fully depreciated property and equipment, at cost | |||||||||
- | - | 7 | 25 | 0 | - | 123 | 129 | 5,839 | - |
Common stock issued in connection with acquired in-process research and development | |||||||||
- | - | - | - | - | 8,648 | 0 | - | - | - |
Promissory note, net of discount, issued in connection with acquired in-process research and development | |||||||||
- | - | - | - | - | 1,364 | 0 | - | - | - |
Contingent rights issued in connection with acquired in-process research and development | |||||||||
- | - | - | - | - | 9,434 | 0 | - | - | - |
Stock issued in connection with milestone payment related to the acquisition of Miikana | |||||||||
- | - | - | - | - | - | - | - | - | 3,000 |